linea guida aiom - terapia del dolore in oncologia - Azienda USL di ...

16-Likar R, Wittels M, Molnar M, et al. Pharmacokinetic and pharmacodynamic properties of
tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther 2006
28: 2022-2039
17-Wiffen PJ, Mc Quay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007 Oct
17;(4):CD003868
18-Hanks GW, DeConno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: The
EAPC recommendations. Br J Cancer 2001; 84:587-593
19-Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E. Oxycodone: a pharmacological and
clinical review Clin Transl Oncol 2007; 9: 298-307
20- Riley J, Eisenberg E, Müller-Schwefe G, et al. Oxycodone: a review of its use in the
management of pain. Curr Med Res Opin 2008, 1: 175-192
21-Reid CM., Martin RM Sterne JA, et al Oxycodone for cancer related pain: meta-analysis of
randomized controlled trials. Arch Intern Med 2006; 166: 837-843
22-Hagen N., Babul N. Comparative clinical efficacy and safety of a novel controlled-release
oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
Cancer 1997; 79:1428-1437
23- Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2007 Oct
17;(4):CD003971
24-Leppert W. The role of methadone in cancer pain treatment-a review. Int J Clin Pract, 2009, 63:
1095-1109
25-Bruera E, Palmer JN, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid
for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185-192
26-Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal
fentanyl and oral methadone in cancer pain management. Eur J Pain 2008; 12: 1040-1046
27-Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev.
2002;(1):CD003447
28-Hanna M., Thipphawong J. A randomized, double-blind comparison of OROS hydromorphone
and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care 2008;
7:17
29-Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and
sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res
Opin 2004; 20: 1419-1428
30-Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on
transdermal fentanyl. Clin Pharmacokinet 2000; 38:59-89
31-Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating
moderate-severe cancer pain in comparison to long acting morphine: a meta-analysis and systematic
review of the literature. J Pall Med 2008; 3: 492-502
32-Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in
cancer patients. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004311.
33-Pergolizzi JV, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the
treatment of cancer pain: an expert panel consensus. Curr Med Res Opin. 2009 May 11
34-Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for
episodic breaktrough pain in patients receiving transdermal buprenorphine. J Pain Symptom
Manage 2006; 32:175-179
35-Mercadante S. Opioid titration in cancer pain: a critical review. Eur J Pain. 2007; 11: 823-830
36-Ripamonti C, Campa T, Fagnoni E, et al. Normal-release oral morphine starting dose in cancer
patients with pain. Clin J Pain 2009; 25:386-390
37-Klepstad P, Kaasa S, Jystad A, et al. Immediate or sustained release morphine for dose finding
during start of morphine to cancer patients: a randomized, double-blind trial. Pain 2003;101:193-
198
38- Jakobsson M, Strang G. Fentanyl patches for the treatment of pain in dying cancer patients
Anticancer Res 1999;19(5C): 4441-4442
40